TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00661986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dark chocolate 6 g/day
Description: dark chocolate 6 g/day
Study: NCT01086254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard
Study: NCT00661986

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dark chocolate 25 g/day
Description: dark chocolate 25 g/day
Study: NCT02673541

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AXIOS™ stent
Description: Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Pigtail Stents
Description: Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
Study: NCT02649322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Tip
Description: After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syringe and 25 gauge needle
Description: The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
Study: NCT02590068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoster vaccine live
Description: Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
Study: NCT05012748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
Study: NCT02241473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
Study: NCT01822561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50mg
Description: All patients will receive the same dose of eplerenone.
Study: NCT01173263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIS 70 maintained
Description: Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIS level 50
Description: Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIS 35
Description: Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
Study: NCT04146987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair surgery
Description: Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair surgery
Description: Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair
Study: NCT01745120

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
Study: NCT00837486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reclaim™ DBS System

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Reclaim™ DBS System
Study: NCT02590068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoster vaccine live
Description: Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
Study: NCT01339364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Lecture
Description: 2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Lecture
Description: 2 sessions of brief interactive lectures followed by case discussion sections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lecture plus Small Group Education
Description: A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
Study: NCT02067351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Meditation, body scan, yoga.
Study: NCT02435823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseRider
Description: Adjunctive device for endovascular embolization of intracranial aneurysms
Study: NCT00763763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: imatinib 600 mg/day for 2 years
Study: NCT04376619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: inflation and deflation of cuff 5min each cycle repeated 3 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KDIGO guidelines
Description: KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
Study: NCT01797718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: 1mg/kg every 4 weeks for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
Study: NCT01305512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1028
Description: SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
Study: NCT00486603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
Study: NCT00763763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: 45 micrograms per week during 2 years
Study: NCT00486603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
Study: NCT00763763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
Study: NCT03904563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: split-course chest radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Study: NCT02294253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: 30 day oral Buprenorphine/naloxone
Study: NCT02536950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed set point
Description: Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable set point
Description: Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
Study: NCT00269776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS (methylphenidate HCl)
Description: Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin (methylphenidate)
Description: Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
Study: NCT03507114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused CBT (RFCBT)
Description: RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings \& vignettes of participants experiences of the therapy.
Study: NCT00435253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR Treatment
Description: BLVR Treatment, 10 mL Hydrogel
Study: NCT02700503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encourage 2.0
Description: Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
Study: NCT03499964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume Drug Coated Balloon (DCB)
Description: The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Treatment
Description: A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
Study: NCT03796845

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No limited movement after surgery
Description: Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No limited movement after surgery
Description: Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
Study: NCT00164944

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: To determine the adenomas during colonoscopy

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: To determine the adenomas during colonoscopy
Study: NCT04023838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: artery puncture and coronary angiography
Description: We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: artery puncture and coronary angiography
Description: We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
Study: NCT02009605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg, oral administration, three times per day.
Study: NCT05466487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Scanning Training (VST)
Description: The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Visual Scanning Training (VST)
Description: The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
Study: NCT02224118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 10 mcg/kg
Description: A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNT0 3649 30 mcg/kg
Description: A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNT0 3649 30 mcg/kg
Description: A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 100 mcg/kg
Description: A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 100 mcg/kg
Description: A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 300 mcg/kg
Description: A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
Study: NCT01673282

Intervention type: DRUG
Intervention: Lacosamide
Description: Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).

Intervention type: DRUG
Intervention: Lacosamide
Description: Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
Study: NCT04322370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Surgical Procedure
Description: Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
Study: NCT02344381

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Study: NCT00486603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation during the first six weeks of treatment Monday-Friday